Arbovax, Inc.

ARBOVAX, Inc. has a unique technology that modifies arthropod-borne viruses (arboviruses) preventing them from replicating in mammalian cells. Arbovax will leverage this technology to facilitate development of a portfolio of improved vaccines against the worldwide threat of arthropod-borne diseases.

Arbovax is an early stage company focused on commercialization of a novel technology to develop improved vaccines against these viruses.

Arbovax’s unique technology offers a platform from which to target a portfolio of diseases, offering improved vaccine development in a cost-effective manner.

Mosquito-borne viruses provide some of the most important examples of emerging and resurgent diseases of global significance. The Arbovax technology can be applied to any of the over 700 known arboviruses, which encompass a wide range of diseases including:

• Dengue Fever
• Japanese Encephalitis
• West Nile Virus
• Yellow Fever

Collectively, these viruses infect over 100 million people annually and put more than 2.5 billion people at risk of infection. In financial terms this represents a total market opportunity in excess of $1 billion.

ARBOVAX, Inc. has a unique technology to produce a mutation in mosquito-borne viruses that prevents them from replicating in mammalian cells. These enveloped viruses contain modified glycoproteins that allow the viruses to replicate efficiently in insect cells but not in mammalian cells. This enables the creation of vaccines that offer the following advantages over existing vaccines:

Safety: virus infects, but cannot replicate to produce infectious progeny in human cells, allowing development of immunity with no overt disease

Efficacy: vaccine provides all epitopes of the wild-type virus (as compared to attenuated viruses or nucleic acid fragments)

Cost: manufacturing process will be less expensive than traditional vaccine production

The company’s initial target will be Dengue fever. An estimated 50 million Dengue infections occur annually world wide, with more than 20,000 deaths. The World Health Organization (WHO) estimates 2.5 billion people are at risk for exposure to this disease.

After initial studies are completed in the U.S., Arbovax intends to continue development of the product in S.E. Asia. The company also will seek corporate partners to facilitate manufacture and distribution of the final product.